Next-generation sequencing (NGS) allows sequencing of a high number of nucleotides in a
short time frame at an affordable cost. While this technology has been widely implemented …

Immunotherapy in non-small cell lung cancer harbouring driver mutations - ScienceDirect Skip
to main contentSkip to article Elsevier logo Journals & Books Search RegisterSign in View …

PURPOSE To provide evidence-based recommendations updating the 2017 ASCO
guideline on systemic therapy for patients with stage IV non–small-cell lung cancer (NSCLC) …

Highlights•NRG1 fusions result in ErbB-mediated pathway activation and present a rational
therapeutic target.•ErbB-targeted treatments, such as afatinib, can be effective therapeutic …

Non-small cell lung cancer (NSCLC) is frequently associated with oncogenic driver
mutations, which play an important role in carcinogenesis and cancer progression …

Abstract Background Neuregulin 1 (NRG1) fusions, which activate ErbB signaling, are rare
oncogenic drivers in multiple tumor types. Afatinib is a pan‐ErbB family inhibitor that may be …

Abstract Purpose of Review Over the last two decades, the identification of targetable
oncogene drivers has revolutionized the therapeutic landscape of non-small cell lung …

The management of non-small cell lung cancer (NSCLC) has transformed with the discovery
of therapeutically tractable oncogenic drivers. In addition to activating driver mutations, gene …

Lung cancer persistently leads as the primary cause of morbidity and mortality among
malignancies. A notable increase in the prevalence of lung adenocarcinoma has become …

NRG1 gene fusions are rare, therapeutically relevant, oncogenic drivers that occur across
solid tumor types. To understand the landscape of NRG1 gene fusions, 4397 solid tumor …